Wu Ping, Fang Xing, Liu Yalan, Tang Yaoyun, Wang Wei, Li Xin, Fan Yuhua
Department of Otorhinolaryngology Head & Neck Surgery; Province Key Laboratory of Otolaryngology Critical Diseases, Xiangya Hospital, Central South University, Changsha, 410008, China.
Cell Death Dis. 2021 Mar 19;12(4):298. doi: 10.1038/s41419-021-03558-2.
Hypopharyngeal squamous cell carcinoma (HPSCC) is one of the most common malignant tumors in otolaryngology head and neck surgery and is one of the worst prognostic malignant tumors. Endogenous circular RNA (circRNA) is more stable than mRNA, microRNA (miRNA), and long non-coding RNA (LncRNA) in exosomes, plasma, and urine, and participates in gene expression regulation to perform different functions. Therefore, circRNA is expected to become a biomarker and therapy target for many tumors. However, the expression and function of circRNA regulated by N6-methyladenosine (m6A) are still unclear in HNSCC. In this study, we demonstrated that a specific circRNA, circCUX1, was upregulated in HPSCC patients who are resistant to radiotherapy and predicts poor survival outcome. We further found that methyltransferase like 3 (METTL3) mediated the m6A methylation of circCUX1 and stabilizes its expression. Knockdown circCUX1 promotes the sensitivity of hypopharyngeal cancer cells to radiotherapy. In addition, circCUX1 binds to Caspase1 and inhibits its expression, resulting in a decrease in the release of inflammatory factors, thereby developing tolerance to radiotherapy. Our findings indicate that circCUX1 is a potential therapeutic target for radiotherapy tolerance in HPSCC patients.
下咽鳞状细胞癌(HPSCC)是耳鼻咽喉头颈外科最常见的恶性肿瘤之一,也是预后最差的恶性肿瘤之一。内源性环状RNA(circRNA)在外泌体、血浆和尿液中比信使核糖核酸(mRNA)、微小核糖核酸(miRNA)和长链非编码核糖核酸(LncRNA)更稳定,并参与基因表达调控以发挥不同功能。因此,circRNA有望成为多种肿瘤的生物标志物和治疗靶点。然而,在头颈部鳞状细胞癌(HNSCC)中,由N6-甲基腺苷(m6A)调控的circRNA的表达和功能仍不清楚。在本研究中,我们证明了一种特定的circRNA,即circCUX1,在对放疗耐药的HPSCC患者中上调,并预示着不良的生存结果。我们进一步发现,甲基转移酶样3(METTL3)介导circCUX1的m6A甲基化并稳定其表达。敲低circCUX1可提高下咽癌细胞对放疗的敏感性。此外,circCUX1与半胱天冬酶1结合并抑制其表达,导致炎症因子释放减少,从而产生放疗耐受性。我们的研究结果表明,circCUX1是HPSCC患者放疗耐受性的潜在治疗靶点。